These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2675082)

  • 21. Transfusional iron overload.
    Marcus RE; Huehns ER
    Clin Lab Haematol; 1985; 7(3):195-212. PubMed ID: 3907937
    [No Abstract]   [Full Text] [Related]  

  • 22. [Serum ferritin in the follow-up of homozygotic beta-thalassemia treated with blood transfusion and iron-chelating agents].
    Esposito L; Ferrara M; Ponte G
    Pediatria (Napoli); 1981 Sep; 89(3):479-92. PubMed ID: 7346759
    [No Abstract]   [Full Text] [Related]  

  • 23. Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major.
    Grosse R; Lund U; Caruso V; Fischer R; Janka GE; Magnano C; Engelhardt R; Dürken M; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():429-32. PubMed ID: 16339692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impairment of cardiac function in a successful full-term pregnancy in a homozygous beta-thalassemia major: does chelation have a positive role?
    Tsironi M; Ladis V; Margellis Z; Deftereos S; Kattamis Ch; Aessopos A
    Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):117-8. PubMed ID: 15866098
    [No Abstract]   [Full Text] [Related]  

  • 25. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ; Grady RW
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Remission from transfusion-dependence in a patient with congenital dyserythropoietic anemia (CDA) and increased intensity of iron chelation.
    Bergmann AK; Tamary H; Neufeld EJ
    Pediatr Blood Cancer; 2009 Dec; 53(6):1167-8. PubMed ID: 19606459
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical and economic burden of infused iron chelation therapy in the United States.
    Payne KA; Desrosiers MP; Caro JJ; Baladi JF; Lordan N; Proskorovsky I; Ishak K; Rofail D
    Transfusion; 2007 Oct; 47(10):1820-9. PubMed ID: 17880607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding iron overload: screening, monitoring, and caring for patients with transfusion-dependent anemias.
    Ault P; Jones K
    Clin J Oncol Nurs; 2009 Oct; 13(5):511-7. PubMed ID: 19793708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exchange blood transfusions for the treatment of leg ulcerations in thalassemia intermedia.
    Aessopos A; Kati M; Tsironi M; Polonifi E; Farmakis D
    Haematologica; 2006 May; 91(5 Suppl):ECR11. PubMed ID: 16709519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recognition and treatment of iron overload.
    Brown EB
    Adv Intern Med; 1980; 26():159-86. PubMed ID: 7013439
    [No Abstract]   [Full Text] [Related]  

  • 31. MRI and iron-overload cardiomyopathy in thalassaemia.
    Pennell D
    Circulation; 2006 Mar; 113(11):f43-4. PubMed ID: 16552847
    [No Abstract]   [Full Text] [Related]  

  • 32. Methods for noninvasive measurement of tissue iron in Cooley's anemia.
    Sheth S; Tang H; Jensen JH; Altmann K; Prakash A; Printz BF; Hordof AJ; Tosti CL; Azabagic A; Swaminathan S; Brown TR; Olivieri NF; Brittenham GM
    Ann N Y Acad Sci; 2005; 1054():358-72. PubMed ID: 16339684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Chelating therapy in beta-thalassemia].
    Musumeci S; Romeo MA; Di Gregorio F; Schiliró G; Russo G
    Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up.
    Gaziev J; Sodani P; Polchi P; Andreani M; Lucarelli G
    Ann N Y Acad Sci; 2005; 1054():196-205. PubMed ID: 16339666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospects for effective oral iron chelation therapy in man with 1,2-dimethyl-3-hydroxypyrid-4-one and other alpha-ketohydroxypyridines.
    Kontoghiorghes GJ; Bartlett AN; Hoffbrand AV
    Prog Clin Biol Res; 1989; 309():107-14. PubMed ID: 2780745
    [No Abstract]   [Full Text] [Related]  

  • 36. Management of beta-thalassemia major using transfusions and iron chelation with deferoxamine.
    Freedman MH
    Transfus Med Rev; 1988 Sep; 2(3):161-75. PubMed ID: 2980085
    [No Abstract]   [Full Text] [Related]  

  • 37. Is there a standard-of-care for transfusion therapy in thalassemia?
    Franchini M; Forni GL; Liumbruno GM
    Curr Opin Hematol; 2017 Nov; 24(6):558-564. PubMed ID: 28719386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of desferal therapy on indices of iron metabolism in patients with intermediate forms of beta-thalassemia].
    Efendieva EG; Dashkova NG
    Gematol Transfuziol; 1987 Sep; 32(9):23-6. PubMed ID: 3692120
    [No Abstract]   [Full Text] [Related]  

  • 39. Preface. Thalassemia.
    Forget BG
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):xiii-xv. PubMed ID: 21075276
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical management of thalassemia. Decreasing iron stores during intensive chelation therapy.
    Cohen A; Schwartz E
    Ann N Y Acad Sci; 1980; 344():405-8. PubMed ID: 6930880
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.